Q4 2025 Earnings Call February 24, 2026 5:00 PM ESTCompany ParticipantsMatt Milanovich - Senior Vice President of ...
Iovance Biotherapeutics, Inc. demonstrates improved Q4 results, with $87M revenue and a 50% gross margin. Learn more about IOVA stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results